Loading
Life sciences · Journal article
Discover Oncology · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Bladder cancer (BC) presents a significant clinical challenge, with a poor prognosis in its advanced stages. Although immunotherapy has improved outcomes, patient response rates remain limited due to complex immune evasion mechanisms. Robust biomarkers are urgently needed for prognostic stratification and to help identify patients who might benefit from immunotherapy. We developed an immune evasion-related signature (IRS) using transcriptomic data from The Cancer Genome Atlas (TCGA) and validated it across four independent Gene Expression Omnibus (GEO) cohorts. An integrative machine learning framework based on ten algorithms, fitted as 60 candidate model configurations, was used to construct the IRS from differentially expressed immune-related genes. The signature’s prognostic value, association with the tumor immune microenvironment (TME), and predictive power for immunotherapy response were assessed, and the key gene DOT1L was functionally validated in vitro. The IRS, comprising five genes (DOT1L, DVAC2, SRRT, PPP2R3C, and IRF9), effectively stratified BC patients into high-risk and low-risk groups. A high IRS score was an independent prognostic factor for poorer overall survival and was associated with an immunosuppressive TME, characterized by reduced CD8 + T cell infiltration and higher Tumor Immune Dysfunction and Exclusion (TIDE) scores. Conversely, low IRS scores correlated with enhanced response to anti-PD-1/L1 therapy in validation cohorts. Furthermore, DOT1L knockdown suppressed BC cell proliferation and migration. We developed and retrospectively validated a machine learning-derived IRS that showed consistent associations with prognosis and immunotherapy benefit across multiple independent bladder cancer cohorts. The IRS is a promising research biomarker, and prospective, multicenter validation is required before it can guide personalized treatment decisions.